Longeveron (NASDAQ:LGVN) jumped after publishing a press release stating that Phase 2a results for its Alzheimer’s treatment met primary endpoints.Lomecel-B is a treatment for mild cases of Alzheimer’s disease. The CLEAR MIND study on 48 patients suggests that the drug slowed progression of the disease.Longeveron remains a penny stock. After jumping 13% on July 26 and nearly 20% in pre-market trading, its market capitalization was still below $60 million.Lomecel-B Lifts LGVN Stock Longeveron was trading nea ...